Global Asset Fund
VC Fund
Landshut, Germany
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Global Asset Fund invests in
Stages Global Asset Fund invests in
Countries Global Asset Fund invests in
Round sizes
Round size
- Series A
- $1M–$1.9M
- Series B
- $1.6M–$2.9M
Investment Focus
Industry
- Biotechnology 2 (22%)
- Medical 1 (11%)
- Health Care 1 (11%)
- Therapeutics 1 (11%)
- Manufacturing 1 (11%)
Stage
- Series A 1 (11%)
- Series B 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- Germany 2 (22%)
- Austria 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, andanalysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably. | Venture - Series Unknown / Sep 01, 2019 | ||
| SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. | $2.9M / Series B / Mar 23, 2017 | ||
| SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. | $1.6M / Series B / Apr 15, 2016 | ||
| SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. | $1.6M / Series B / May 15, 2015 | ||
| SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. | $1M / Series A / Jun 30, 2014 | ||
| Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. | $7.6M / Apr 24, 2014 | ||
| SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. | $1.9M / Series A / Apr 13, 2013 | ||
| Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. | $8.8M / Jul 07, 2011 | ||
| Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. | $14.3M / Mar 15, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Global Asset Fund invest in?
Global Asset Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Global Asset Fund's check size?
Global Asset Fund typically joins rounds of $1M–$1.9M at Series A and $1.6M–$2.9M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Global Asset Fund participates in.
When did Global Asset Fund last invest?
The most recent investment recorded for Global Asset Fund closed in Sep 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
